Profile: Trinity Biotech PLC (TRIB.O)
29 Jul 2016
Trinity Biotech plc (Trinity Biotech), incorporated on January 22, 1992, develops, acquires, manufactures and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market. The Company's products are used to detect autoimmune, infectious and sexually transmitted diseases, diabetes, and disorders of the liver and intestine. It operates through two segments: the Americas and Rest of World. Trinity Biotech is a provider of raw materials to the life sciences and research industries around the world. Trinity Biotech markets its portfolio of approximately 850 products to customers in approximately 100 countries around the world, through its sales force and a network of international distributors and strategic partners. The primary market for Trinity Biotech's diagnostic products is the Americas, which consists of North America and South America. Trinity Biotech also sells raw materials to the life sciences industry and research institutes around the world, through its subsidiary, Benen Trading Ltd., trading as Fitzgerald Industries. Trinity Biotech sells its products through its direct sales organizations in the United States, Brazil and the United Kingdom, and through a network of principal distributors and non-governmental bodies into approximately 100 countries around the world. The Company's products are classified as POC, emergency medicine, clinical laboratory and blood bank screening.
POC refers to diagnostic tests, which are carried out in the presence of the patient. The Company's POC brands include Uni-Gold and Recombigen. Trinity Biotech offers products, such as Uni-Gold HIV, Uni-Gold S. pneumoniae, Uni-Gold Legionella, Uni-Gold C. difficile and Uni-Gold Syphilis.
Emergency medicine diagnostics refer to the Company's acute care testing, which are diagnostic tests performed in emergency rooms, STAT labs, pre/post-operative units, physician office labs and the central laboratory. Troponin I is a marker for detecting acute myocardial infarctions. The Company offers a Brain Natriuretic Peptide (BNP) test. BNP is a biomarker utilized in aiding the diagnosis of and determining the clinical severity of heart failure. In addition, BNP is useful in a range of clinical applications, including risk stratification and monitoring of patients with heart failure and heart attacks.
The Company is focused on expanding its offering on the Meritas POC Analyser. The focus of the Company's development efforts is to continue to expand the test menu to include assays for deep vein thrombosis and pulmonary embolism (D-dimer), and other areas of need in emergency medicine. Trinity Biotech offers the Meritas Troponin and BNP products for sale in Europe and other selected markets through its specialist Cardiology Distributor network.
Trinity Biotech supplies the clinical laboratory segment of the in-vitro diagnostic market with a range of diagnostic tests and instrumentation, which detect infectious diseases; hemoglobin, hemoglobin variants and glycated hemoglobin used in monitoring diabetes and autoimmune diseases. Trinity Biotech also supplies clinical laboratory market with reagent products and other products through its clinical chemistry business. The Company offers clinical laboratory products under brands, including Bartels, MarDx, MarBlot, Premier, Ultra2, ImmuBlot, ImmuGlo, ImmuLisa, OTOblot and EZ.
Trinity Biotech manufactures products for applications in infectious diseases. The products are used with patient samples, and the results generated help physicians to guide diagnosis for a range of infectious diseases, which include Lyme disease; sexually transmitted diseases, including syphilis, chlamydia and herpes simplex virus; respiratory infections, including legionella and influenza; Epstein Barr virus, and other viral pathogens, including measles, mumps, rubella and varicella. Trinity Biotech develops, manufactures and distributes products in immunofluorescence (IFA), enzyme-linked immunosorbent (ELISA), western blot (WB) and cytotoxicity assay formats for diagnosis of infectious diseases. The Company's automation offering includes ELISA and WB processors.
The Company manufactures products for in-vitro diagnostic testing for hemoglobin A1c (HbA1c) used in the monitoring and diagnosis of diabetes, as well identifying those at a risk of developing diabetes (pre-diabetic). Trinity Biotech manufactures its own A1c instrument, the Premier Hb9210. The Premier Hb9210 uses boronte affinity technology to test for HbA1c. HbA1c is also used to identify those at risk of becoming diabetic. Trinity Biotech develops and commercializes products for hemoglobin variants, primarily through the Ultra2 instrument. This is used for the detection of hemoglobinapothies.
Trinity Biotech operates through Immco Diagnostics, an autoimmunity company known for assay development and impactful contributions to autoimmune disease diagnostic research. Immco Diagnostics develops, manufactures and distributes products in various formats for diagnosis of autoimmune diseases, including IFA, ELISA, WB and line immunoassay (LIA). The Immco Diagnostics' products are sold through Trinity Biotech's sales and marketing organization to clinical and reference laboratories in the United States, and through distributors in other countries. The specialty clinical chemistry business of Trinity Biotech includes reagent products, such as angiotensin converting enzyme (ACE), bile acids, lactate, oxalate and glucose-6-phosphate dehydrogenase (G6PDH).
Blood Bank Screening
Trinity Biotech's blood bank screening business unit manufactures a number of products to screen donated blood for transfusion-transmissible infections. The Company offers blood bank screening products under Captia and MicroTrak brands. Trinity Biotech manufactures immunoassays for the detection of syphilis, Cytomegalovirus (CMV) and malaria. The blood bank products are sold through direct and distributor sales channels, and are manufactured under original equipment manufacturer agreements for other third party diagnostic companies.
The Company competes with Abbott Diagnostics, Arkray, Bio-Rad, Diasorin Inc., Euroimmun, Johnson & Johnson, OraSure Technologies Inc., Phadia, Roche Diagnostics, Siemens, Thermo Fisher, Tosoh and Werfen.
Trinity Biotech PLC
IDA Business Park